Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ALPACA
- 18 Apr 2016 Status changed from not yet recruiting to recruiting.
- 18 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 06 Oct 2015 New trial record